Cardiac Complications in Immune Checkpoint Inhibition Therapy

Frontiers in Cardiovascular Medicine

article

Kazuko Tajiri¹  Masaki Ieda¹ 

[1] Department of Cardiology, Faculty of Medicine, University of Tsukuba

关键词: immune checkpoint inhibitors;    myocarditis;    cardiotoxicity;    programmed cell death protein 1;    cytotoxic T-lymphocyte antigen 4;    immune-related adverse events;    immune checkpoint;    autoimmunity;   

DOI  :  10.3389/fcvm.2019.00003

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of advanced cancers. Unfortunately, these agents can induce a wide spectrum of immune-related adverse events (irAEs) through activation of immune responses in non-target organs, including the heart. As the clinical use of ICI therapy increases rapidly, management of irAEs is becoming extremely important. The most commonly presented cardiac irAE is myocarditis. Histopathologically, T-cell (with a predominance of CD8 + cells) and macrophage infiltration in the myocardium is typically observed in ICI-associated myocarditis. Other presentations of cardiac irAEs include congestive heart failure, Takotsubo cardiomyopathy, pericardial disease, arrhythmias, and conduction disease. Although cardiac irAEs are relatively rare, they can be life-threatening. Hence, cardiologists and oncologists should be vigilant for these presentations.

【 授权许可】

CC BY